Exhaled breath analysis for lung cancer detection using ion mobility spectrometry

应用离子迁移谱（IMS）对61例经支气管镜证实的肺癌患者呼出气进行分析，并与40例健康志愿者进行比较。作为次要评估，我们比较了有和没有表皮生长因子受体（EGFR）突变的腺癌患者。统计分析了105个分离的挥发性有机化合物（VOC）峰。其中，13个峰显示出显著更高的肺癌水平（p<0.05）。正十二烷是区分肺癌和健康受试者的最重要的生物标志物，灵敏度为90%，特异性为69%。以正十二烷峰为起始点建立决策树算法，灵敏度为100%，特异性为93%。15例携带EGFR突变的腺癌患者显示出显著高于17例无EGFR突变的腺癌患者的正十二烷峰，灵敏度为53%，特异性为100%（p<0.01）。

The exhaled breath of 61 patients with lung cancer confirmed by bronchoscopy, were analyzed using ion mobility spectrometry (IMS) and compared with 40 healthy volunteers. As a secondary assessment, we compared adenocarcinoma patients with and without epidermal growth factor receptor (EGFR) mutation. One hundred-five separated volatile organic compound (VOC) peaks were analyzed statistically. Of these, thirteen peaks showed significantly higher levels of lung cancer (p<0.05). n-Dodecane was the most important biomarker to discriminate between lung cancer and healthy subjects with a sensitivity of 90% and a specificity of 69%. Incorporating a decision tree algorithm starting with n-Dodecane peak, a sensitivity of 100 % and specificity of 93 % was achieved. Fifteen adenocarcinoma patients harboring EGFR mutation displayed a significantly higher n-Dodecane peak with a sensitivity of 53 % and a specificity of 100 % (p<0.01) than in 17 adenocarcinoma patients without the EGFR mutation.